

—
THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANSLATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET

SenzaGen approved for trading on Nasdaq First North

SenzaGen AB ("SenzaGen" or "the Company") has today been approved by Nasdaq Stockholm AB as an issuer of shares on Nasdaq First North in Stockholm. The first trading day for the Company's shares is 21st September 2017.

At the request of Nasdaq Stockholm AB, the Company has provided certain additional information relating to its listing on Nasdaq First North, and this information has been collated in the document "*Additional information in relation to listing on Nasdaq First North*" which is available on the Company's website www.senzagen.com/investors/prospekt-listning-nasdaq-first-north/.

The share offer for listing on Nasdaq First North

The application period for SenzaGen's offer for the Company's listing on Nasdaq First North ended on September 12th 2017. The offer was addressed to both institutional and professional investors as well as to the general public in Sweden. Through the share issue, the Company has acquired more than 1,000 new shareholders.

Certified Adviser and Issuing agent

Vator Securities are the Company's financial adviser and Baker McKenzie is the Company's legal adviser. The issuing agent for the transaction is Nordnet Bank.

Further information

For further information, please refer to the Prospectus, which has been approved by and registered with the Swedish Financial Supervisory Authority with regard to the share issue, prior to the planned listing on Nasdaq First North. NOT RELEVANT FO MARKET OUTSIDE SWEDEN

For further information, please visit the Company's website, www.senzagen.com or contact: Anki Malmberg Hager, CEO of SenzaGen AB, email: anki.malmberg.hager@senzagen.com, telephone: +46 76 828 48 22.

About GARD

GARD™ is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability.

This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently, GARD™ tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen

SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

Important information

This announcement is not and does not form a part of any offer for sale of securities.

Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan, New Zealand, South Africa, Hong Kong, Singapore or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.

An offering of the securities referred to in this announcement is made by means of the prospectus referred to herein. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive"). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.

SENZAGEN AB

MEDICON VILLAGE,
SCHEELEVÄGEN 2
223 81 LUND, SWEDEN

P: +46 46 2756200
W: WWW.SENZAGEN.COM
E: INFO@SENZAGEN.COM

—

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “will,” “may,” “continue,” “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.